Home > Journals > Minerva Psichiatrica > Past Issues > Minerva Psichiatrica 1999 March;40(1) > Minerva Psichiatrica 1999 March;40(1):1





A Journal on Psychiatry, Psychology and Psychopharmacology

Official Journal of the Italian Society of Social Psychiatry
Indexed/Abstracted in: EMBASE, e-psyche, PsycINFO, Scopus, Emerging Sources Citation Index




Minerva Psichiatrica 1999 March;40(1):1


language: Italian

Psychopharmacological treatment of Burning Mouth Syndrome (BMS). A study on a sample of 121 patients

Bogetto F., Bonatto Revello R., Ferro G., Maina G., Ravizza L.


Background. Burning mouth syndrome (BMS) is a clinical condition characterized by burning and/or pain in a mouth with normal mucosa.
Literature indicates a considerable association among this disorder and some psychopathologic elements, in particular depression and anxiety. Many authors assert an etiopathogenetic assumption of psychic kind, in addition to the more traditional somatic hypotheses.
Few researches have examined BMS psychopharmacologic treatment, although reporting that psychopharmacologic drugs give have good results in BMS. This study is directed to verify the efficacy and the tolerance of some psychopharmacologic treatments in a group of BMS patients.
Methods. The BMS group (121 patients) has been divided according to the random criterion into 5 subgroups, each one treated in a condition of open label with a different drug (paroxetine, amitriptiline, clordemetildiazepam, amisulpride, placebo). The group was evaluated at T0 (baseline), T1 (4 weeks), T2 (8 weeks) through: semistructured clinical interview to investigate also BMS clinical characteristics; HARS to evaluate anxious symptoms, MADRS for depressive symptoms and CGI I for BMS symptoms. A statistical analysis of score variations to assessment scales, caused by different treatments, has been made, considering the number of drops-out recorded at each time of assessment for each drug used.
Results and conclusions. From the results obtained it can be seen, besides a remarkable comorbidity with mood and anxiety disorders, the efficacy of the psychopharmacologic drugs used to improve the anxious and depressive symptomatology and BMS symptoms. In the latter two cases a statistical significance has been achieved only by amisulpride.

top of page

Publication History

Cite this article as

Corresponding author e-mail